Advanced Biomed Inc. Announces 120‑Case Feasibility Study with Chi‑Mei Medical Center to Validate A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Core Insights - Advanced Biomed Inc. has entered into a clinical research collaboration with Chi-Mei Medical Center to conduct a 120-case feasibility study on its A+PerfusC platform, aimed at evaluating predictive accuracy in oncology treatment selection [1][2]. Group 1: Study Details - The feasibility study is a non-interventional clinical research project approved by the Institutional Review Board, with case collection starting in early February 2026 and full completion targeted by year-end 2026 [2]. - Interim comparative data from the study is expected in May–June 2026, focusing on the correlation between drug sensitivity results from the A+PerfusC platform and actual patient clinical outcomes [2][4]. Group 2: Technological Advantages - The A+PerfusC platform utilizes label-free microfluidic technology to isolate high-viability circulating tumor cells, enabling automated 3D culture arrays for parallel drug testing, which addresses limitations of traditional 2D models and xenograft animal models [3][4]. - This innovative approach aims to reduce the time to evidence-based treatment decisions and minimize patient exposure to ineffective therapies [3]. Group 3: Collaboration and Future Plans - The collaboration with Chi-Mei Medical Center will involve joint clinical research and commercial development, with both parties sharing rights to project-related intellectual property and research outcomes [5]. - The results from the feasibility study are expected to inform the design of larger clinical validation studies and support the A+PerfusC platform's use as a predictive tool for treatment response [4]. Group 4: Company Overview - Advanced Biomed Inc. specializes in innovative biomedical technologies for cancer detection and precision medicine, operating through a subsidiary in Taiwan [6][7]. - The company has developed a proprietary microfluidic platform for advanced circulating tumor cell detection, with plans for regulatory clearances in Taiwan and future global expansion [7].